MERTK is involved in multiple malignancies, including leukemia, glioma, melanoma, and rhabdomyosarcoma [35,36], while it has been described as novel therapeutic target in several of these malignancies [36]. This evidence concerns the gene MERTK and rhabdomyosarcoma.